The FDA announced it is now receiving public comments on the development and evaluation of abuse-deterrent formulations of central nervous system stimulants and whether such products could play a role in addressing public health concerns over prescription stimulant misuse.
Fentanyl overdose deaths climbed 14% in 2018, per CDC data, and a report released this week by not-for-profits Drug Strategies and Shatterproof studies the states hit hardest and how they have responded.
The first supervised injection facility in the United States is one step closer to opening after a U.S. district judge ruled that a Philadelphia not-for-profit’s project does not violate federal drug laws.
During its 15th annual Hill Day in Washington, D.C., the National Council for Behavioral Health unveiled a five-pronged campaign to expand access to treatment, enforce parity laws and grow the mental health and addiction treatment workforce.
Speaking out about political leadership can be costly for mental healthcare professionals. Yet, in this time of escalating political polarization, mental health professionals and organizations do have the ethical challenge of what, if anything, to say and do about our current situation.
The Substance Abuse and Mental Health Services Administration has proposed a series of revisions to 42 CFR Part 2 regulations to facilitate better care coordination for the treatment of substance use disorders.
The Medicaid demonstration program for certified community behavioral health clinics (CCBHCs) that was originally slated to expire at the end of June has been granted an extension to continue into September.